News

15 September 2017
Artios Pharma wins Life Science Young Company of the Year and UK Private Finance Raise at the Biotech and Money Annual Awards 2017

Cambridge, UK, 15 September 2017. Artios Pharma Ltd., a leading DNA Damage Response (DDR) company developing innovative new treatments for cancer, is pleased to announce that it has won the “Life Science Young Company of the Year” and “UK Private Finance Raise of the Year” awards at last night’s Biotech and Money Awards 2017.

Dr Niall Martin, Chief Executive Officer of Artios Pharma, said: “I am delighted that Artios Pharma has been recognised by its peers through these two awards. Artios is building a pipeline of highly innovative, next generation DDR targeted therapies for the treatment of cancer, and these awards are testament to all the hard work and effort that the team at Artios, together with our high-calibre investors and collaborators, have put in since launch.”

The Biotech and Money Awards recognise the UK and Ireland’s greatest funding, investment and deal making successes in the sector through 12 hotly contested Awards, providing the opportunity for life science Executives to recognise, influence and celebrate the achievements of their peers.

The Life Science Young Company of the Year Award recognises privately owned Life Science companies that are between one and three years on from incorporation and have demonstrated credibility in terms of business model, strategy, management team, financing and ability to move therapeutic candidates through pre-clinical / clinical stages to target unmet medical needs.

The UK Private Finance Raise of the Year (less than £25m) Award recognises privately owned Life Science companies that have secured significant new funds for growth or strategic development. The amount and source of funds raised, the reputation of investors, value creation and post-finance performance are included in the criteria for winning the award.

About Artios Pharma Ltd.
Artios is a leading DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. Established in May 2016, the Company is led by an experienced scientific and leadership team with proven expertise in DDR drug discovery. Artios is building a pipeline of next-generation DDR programmes, including through a unique partnership with Cancer Research UK (CRUK), and with leading DNA repair researchers worldwide. The Company’s investors include SV Health Investors, Merck Ventures, Touchstone Innovations, Arix Bioscience plc, CRT Pioneer Fund (managed by Sixth Element Capital), and AbbVie Ventures. Artios is based at the Babraham Research Campus in Cambridge, UK.

About DNA Damage Response (DDR)
DNA Damage occurs in cells throughout the body every day. To counteract the harmful effects that DNA damage can cause, the human body possesses a network of DNA repair pathways, which act to correct the damage. This process is known as the DNA Damage Response (DDR). Defects in the body’s DDR can lead to an increased risk of cancer. Human cells have multiple DNA repair pathways, but in cancer cells, some of these pathways are lost, which result in genetic instability. Changes to DNA repair pathways can also drive the growth of tumours. By inhibiting DDR in cancer cells that have impaired repair pathways, scientists can selectively kill cancerous cells. DDR inhibitors, therefore, have the potential to act as: single agents that selectively kill tumour cells through synthetic lethality; adjunctive therapy to overcome resistance to current cytotoxics, and potentiating agents to radiotherapy and novel therapies including immune-oncology treatments.

Back